Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

875 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sustainable metabolic engineering requires a perfect trifecta.
Nurwono G, O'Keeffe S, Liu N, Park JO. Nurwono G, et al. Among authors: park jo. Curr Opin Biotechnol. 2023 Oct;83:102983. doi: 10.1016/j.copbio.2023.102983. Epub 2023 Aug 11. Curr Opin Biotechnol. 2023. PMID: 37573625 Review.
Atlas of fetal metabolism during mid-to-late gestation and diabetic pregnancy.
Perez-Ramirez CA, Nakano H, Law RC, Matulionis N, Thompson J, Pfeiffer A, Park JO, Nakano A, Christofk HR. Perez-Ramirez CA, et al. Among authors: park jo. Cell. 2024 Jan 4;187(1):204-215.e14. doi: 10.1016/j.cell.2023.11.011. Epub 2023 Dec 8. Cell. 2024. PMID: 38070508 Free article. Review.
M2 isoform of pyruvate kinase rewires glucose metabolism during radiation therapy to promote an antioxidant response and glioblastoma radioresistance.
Bailleul J, Ruan Y, Abdulrahman L, Scott AJ, Yazal T, Sung D, Park K, Hoang H, Nathaniel J, Chu FI, Palomera D, Sehgal A, Tsang JE, Nathanson DA, Xu S, Park JO, Ten Hoeve J, Bhat K, Qi N, Kornblum HI, Schaue D, McBride WH, Lyssiotis CA, Wahl DR, Vlashi E. Bailleul J, et al. Among authors: park jo, park k. Neuro Oncol. 2023 Nov 2;25(11):1989-2000. doi: 10.1093/neuonc/noad103. Neuro Oncol. 2023. PMID: 37279645
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
Li BT, Meric-Bernstam F, Bardia A, Naito Y, Siena S, Aftimos P, Anderson I, Curigliano G, de Miguel M, Kalra M, Oh DY, Park JO, Postel-Vinay S, Rha SY, Satoh T, Spanggaard I, Michelini F, Smith A, Machado KK, Saura C; DESTINY-PanTumor01 study group. Li BT, et al. Among authors: park jo. Lancet Oncol. 2024 May 3:S1470-2045(24)00140-2. doi: 10.1016/S1470-2045(24)00140-2. Online ahead of print. Lancet Oncol. 2024. PMID: 38710187
875 results